Drug Profile
Hormonal therapy for bronchopulmonary dysplasia - Adepthera
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Adepthera
- Class
- Mechanism of Action G protein-coupled receptor agonists; Signal transducing adaptor protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bronchopulmonary dysplasia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Bronchopulmonary-dysplasia in USA
- 12 Aug 2016 Preclinical trials in Bronchopulmonary dysplasia in USA (unspecified route)